Advanced gastric cancer with peritoneal dissemination successfully treated with paclitaxel and doxifluridine: A case report

Hepato-Gastroenterology

Volumn 52, Issue 61, 2005, Pages 322-325

  Takeyoshi, Izumi ^a   Iwanami, Kotaro ^a   Yamada, Tatsuya ^a   Kawate, Susumu ^a   Hamada, Kunihiro ^a   Sunose, Yutaka ^a   Yoshida, Miho ^a   Horiguchi, Jun ^a   Ohwada, Susumu ^a   Sasaki, Atsushi ^a   Morishita, Yasuo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Doxifluridine; Gastric cancer; Paclitaxel; Thymidine phosphorylase

Indexed keywords

DOXIFLURIDINE; PACLITAXEL; TEGAFUR; THYMIDINE PHOSPHORYLASE;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; APOPTOSIS; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DERMATITIS; DRUG EFFICACY; DRUG TOLERABILITY; ENDOSCOPY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MYALGIA; PERITONEUM METASTASIS; PRIORITY JOURNAL; RECTOUTERINE POUCH; SIGNET RING CARCINOMA; STOMACH BIOPSY; STOMACH CANCER; STOMACH WALL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SIGNET RING CELL; FEMALE; FLOXURIDINE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PACLITAXEL; PENTOSYLTRANSFERASES; PERITONEUM; STOMACH NEOPLASMS;

EID: 20044387393     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587-591.
2. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17:319-323.
3. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin CH: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989; 338:557-562.
4. Sumizawa T, Furokawa T, Haraguchi M, Yoshimura A, Takeyasu A, Ishizawa M, Yamada Y, Akiyama S: Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J Biochem (Tokyo) 1993; 114:9-14.
5. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
6. Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T: Postoperative staging of gastric carcinoma. A comparison between the UICC stage classification and the 12th edition of the Japanese General Rules for Gastric Cancer Study. Scand J Gastroenterol 1996; 31:476-480.
7. Matsumoto S, Kiba T, Numata K, Ihata Y, Morita K, Kitamura T, Saito S, Nakatani Y, Tanaka K, Sekihara H: Advanced gastric cancer associated with DIG successfully treated with 5-FU and cisplatin: a case report. Hepatogastroenterology 2002; 49:153-156.
8. Sato A, Shimada K, Nakamachi M, Ushio J, Yamamoto W, Kurihara M, Matsukawa M: Effectiveness of doxi-fluridine (5′-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens. Gastric Cancer 2002; 5:233-236.
9. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW: Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48:4093-4100.
10. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K: High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells Leukemia 1994; 8:1960-1969.
11. Haldar S, Jena N, Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995; 92:4507-4511.
12. Haldar S, Chintapalli J, Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56:1253-1255.
13. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R, Taguchi T: An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998; 21:416-419.
14. Gori S, Mosconi AM, Basurtol C, Cherubinil R, De Angelis V, Tonato M, Colozza M: Weekly paclitaxel in metastatic breast cancer patients: a phase II study. Tumori 2002; 88:470-473.
15. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
16. Niitani H, Kimura K, Saito T, Nakao I, Abe O, Urushizaki I, Ohta K, Yoshida Y, Kimura T, Kurihara M, et al: [Phase II study of 5′-deoxy-5- fluorouridine (5′-DFUR) in patients with malignant cancer - a multi-institutional cooperative study]. Gan To Kagaku Ryoho 1985; 12:2044-2051. (In Japanese with English abstract)
17. Diasio RB Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16:215-237.
18. Fujimoto-Ouchi K, Tanaka Y, Tominaga T: Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001; 7:1079-1086.